Evolution of Antisense Oligonucleotides: Navigating Nucleic Acid Chemistry and Delivery Challenges

Overview

Journal Expert Opin Drug Discov

Specialties Chemistry
Pharmacology

Date 2024 Dec 9

PMID 39653607

Authors

Ruchi Ruchi

Govind Mukesh Raman

Vikas Kumar

Raman Bahal

Affiliations

Soon will be listed here.

Abstract

Introduction: Antisense oligonucleotide (ASO) was established as a viable therapeutic option for genetic disorders. ASOs can target RNAs implicated in various diseases, including upregulated mRNA and pre-mRNA undergoing abnormal alternative splicing events. Therapeutic applications of ASOs have been proven with the Food and Drug Administration approval of several drugs in recent years. Earlier enzymatic stability and delivery remains a big challenge for ASOs. Introducing new chemical modifications and new formulations resolving the issues related to the nuclease stability and delivery of the ASOs. Excitingly, ASOs-based bioconjugates that target the hepatocyte have gained much attraction. Efforts are ongoing to increase the therapeutic application of the ASOs to the extrahepatic tissue as well.

Area Covered: We have briefly discussed the mechanism of ASOs, the development of new chemistries, and delivery strategies for ASO-based drug discovery and development. The discussion focuses more on the already approved ASOs and those in the clinical development stage.

Expert Opinion: To expand the clinical application of ASOs, continuous effort is required to develop precise delivery strategies for targeting extrahepatic tissue to minimize the off-target effects.

References

Loke S, Stein C, Zhang X, Mori K, Nakanishi M, Subasinghe C . Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989; 86(10):3474-8. PMC: 287160. DOI: 10.1073/pnas.86.10.3474. View

Jafri M, Ansari S, Alqahtani M, Shay J . Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016; 8(1):69. PMC: 4915101. DOI: 10.1186/s13073-016-0324-x. View

Shadid M, Badawi M, Abulrob A . Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol. 2021; 17(11):1281-1292. DOI: 10.1080/17425255.2021.1992382. View

. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002; 133(4):467-74. DOI: 10.1016/s0002-9394(02)01327-2. View

Tsurusaki T, Sato K, Imai H, Hirai K, Takahashi D, Wada T . Convergent synthesis of phosphorodiamidate morpholino oligonucleotides (PMOs) by the H-phosphonate approach. Sci Rep. 2023; 13(1):12576. PMC: 10400599. DOI: 10.1038/s41598-023-38698-2. View

Terada C, Oh K, Tsubaki R, Chan B, Aibara N, Ohyama K . Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry. Nat Commun. 2023; 14(1):7972. PMC: 10693639. DOI: 10.1038/s41467-023-43714-0. View

Quemener A, Centomo M, Sax S, Panella R . Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development. Molecules. 2022; 27(2). PMC: 8781596. DOI: 10.3390/molecules27020536. View

Xu H, Li Z, Si J . Nanocarriers in gene therapy: a review. J Biomed Nanotechnol. 2015; 10(12):3483-507. DOI: 10.1166/jbn.2014.2044. View

Tassone P, Di Martino M, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D . Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. J Hematol Oncol. 2023; 16(1):68. PMC: 10294514. DOI: 10.1186/s13045-023-01468-8. View

10.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

11.

Roehr B . Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care. 2001; 4(10):14-6. View

12.

Yakubov L, Deeva E, Zarytova V, Ivanova E, Ryte A, Yurchenko L . Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?. Proc Natl Acad Sci U S A. 1989; 86(17):6454-8. PMC: 297862. DOI: 10.1073/pnas.86.17.6454. View

13.

Zhang L, Liang X, De Hoyos C, Migawa M, Nichols J, Freestone G . The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'--Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs. Nucleic Acid Ther. 2022; 32(5):401-411. PMC: 9595634. DOI: 10.1089/nat.2022.0005. View

14.

Mangla P, Vicentini Q, Biscans A . Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Cells. 2023; 12(18). PMC: 10527716. DOI: 10.3390/cells12182253. View

15.

Nie T . Eplontersen: First Approval. Drugs. 2024; 84(4):473-478. PMC: 11101359. DOI: 10.1007/s40265-024-02008-5. View

16.

Hermann T, Patel D . Adaptive recognition by nucleic acid aptamers. Science. 2000; 287(5454):820-5. DOI: 10.1126/science.287.5454.820. View

17.

Oberemok V, Laikova K, Repetskaya A, Kenyo I, Gorlov M, Kasich I . A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. Molecules. 2018; 23(6). PMC: 6099785. DOI: 10.3390/molecules23061302. View

18.

Shen W, De Hoyos C, Migawa M, Vickers T, Sun H, Low A . Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019; 37(6):640-650. DOI: 10.1038/s41587-019-0106-2. View

19.

Ramasamy T, Ruttala H, Munusamy S, Chakraborty N, Kim J . Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Control Release. 2022; 352:861-878. DOI: 10.1016/j.jconrel.2022.10.050. View

20.

Krieg A . Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007; 4(3):289-94. PMC: 2647632. DOI: 10.1513/pats.200701-021AW. View